Roth Capital analyst Boobalan Pachaiyappan initiated coverage of NeuroSense (NRSN) with a Buy rating and $3 price target The firm is positive on PrimeC’s ability to reduce disability and improve survival in amyotrophic lateral sclerosis patients. It estimates PrimeC achieving a peak risk-unadjusted worldwide revenue of $1.5B in 2038.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial
- NeuroSense reports additional long-term survival data from PARADIGM 2b trial
- NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase
- NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042
- NeuroSense granted Australian patent covering PrimeC composition